Navigation Links
Study Demonstrates Glysure System's Ability to Accurately Measure Blood Glucose Levels in the ICU

OXFORD, England, August 28, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced that a study demonstrating the effectiveness of its technology in continuously measuring blood glucose levels in post-surgical cardiac surgery patients will be presented at the World Federation of Societies of Intensive and Critical Care Medicine (WFSICCM) Congress being held this week in Durban, South Africa.

For the study, Use of an intravascular continuous blood glucose sensor during post operative ICU care of cardiac surgery patients, researchers used the GlySure CBGM system to measure blood glucose concentrations in 24 post cardiac surgery ICU patients continuously and in real-time. Blood samples were taken at regular intervals and the glucose concentrations measured. At the time of sampling, the GlySure monitor was time stamped to allow subsequent statistical analysis between the continuous GlySure sensor and the intermittent glucose values.

The researchers found glucose concentrations measured by the GlySure system correlated with the concentrations measured in the blood draws. They concluded the system can dramatically reduce the need for frequent intermittent sampling and offers the potential for early identification of hypoglycemic and hyperglycaemic excursions.

"We are excited by these results," said Principal Investigator Dr. Krishna Prasad. "A device like this would be extremely valuable in managing these kinds of patients in the ICU. The system is also easy to set up and use, which are key requirements in critical care."

GlySure recently commenced a multi-center CE Trial on cardiac surgery patients, which the company expects to complete this fall.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe.

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870.
Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127.

SOURCE GlySure Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
2. New Study Explores Medical Affairs Capabilities in Mature and High-Growth Markets
3. Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
4. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
5. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
6. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
7. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
8. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
9. Astellas Confirms Interim Analysis in PREVAIL Study of XTANDI will Occur within Calendar Year 2013
10. Physicians Expect More Out of Tablet-Toting Pharmaceutical Sales Reps, Study Finds
11. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
Post Your Comments:
(Date:11/26/2015)... 26, 2015 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ... which demands kidney transplantation is expected to boost the market ... for organ transplantation. --> 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
Breaking Medicine Technology:
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... Khanna Vision ... Board of Ophthalmology on November 25th 2015. Peer Certification by the Board ... of his specialty. Certification in Ophthalmology is first obtained after the completion of three ...
(Date:11/29/2015)... IL (PRWEB) , ... November 29, 2015 , ... Effective ... In addition starting on Black Friday Target is offering a “Buy One ... This is a rare opportunity to purchase IguanaMed at a discounted price. ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
Breaking Medicine News(10 mins):